Comparative Pharmacology
Head-to-head clinical analysis: CEFIXIME versus DOCIVYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIXIME versus DOCIVYX.
CEFIXIME vs DOCIVYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
400 mg orally once daily or 200 mg orally every 12 hours for 7–14 days; uncomplicated gonorrhea: 400 mg orally as a single dose
75 mg/m2 intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; extends to 11-15 hours in moderate renal impairment (CrCl 20-40 mL/min) and up to 20 hours in severe impairment.
Clinical Note
moderateCefixime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefixime."
Clinical Note
moderateCefixime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefixime."
Clinical Note
moderateWarfarin + Cefixime
"Warfarin may increase the anticoagulant activities of Cefixime."
Clinical Note
moderatePhenprocoumon + Cefixime
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
Renal excretion of unchanged drug accounts for 50-60% of elimination; biliary/fecal elimination accounts for 10-20%.
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefixime."